ReviewJournal of anaesthesiology, clinical pharmacology
Anesthetic implications in hyperthermic intraperitoneal chemotherapy.
Review in Journal of anaesthesiology, clinical pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 25 citations in OpenAlex.
- Risk factors for complications after cytoreductive surgery (CRS) and HIPEC in 290 peritoneal malignancies of primary and secondary origins.Updates in surgery · 2026Article
- Retrospective evaluation of anesthesia management and clinical outcomes in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.BMC anesthesiology · 2025Observational
- Negative Pressure Wound Therapy to Reduce Surgical Site Infections after CRS/HIPEC.Annals of surgical oncology · 2024Article
- Nursing care for cytoreduction and hyperthermic intraoperative chemotherapy in an Intensive Care Unit: a scoping review.Revista da Escola de Enfermagem da U S P · 2024Article
- Hematological Alterations after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.Journal of clinical medicine · 2023Article
- Perioperative anaesthetic management in cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC): a retrospective analysis in a single tertiary care cancer centre.Pleura and peritoneum · 2022Article
- Anesthetic concerns during cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.Korean journal of anesthesiology · 2021Article
- Onco-Anaesthesiology and palliative medicine: Opportunities and challenges.Indian journal of anaesthesia · 2021Article
- Article
- Rebound hypothermia after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) and cardiac arrest in immediate postoperative period: a report of two cases and review of literature.Pleura and peritoneum · 2020Article
- Society of Onco-Anaesthesia and Perioperative Care consensus guidelines for perioperative management of patients for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC).Indian journal of anaesthesia · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with peritoneal carcinomatosis were considered incurable with dismal survival rates till hyperthermic intraperitoneal chemotherapy after optimal cytoreductive surgery evolved. Perioperative management for these procedures is complex and involves an optimal cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy. In this article we highlight the perioperative concerns in these patients including anesthetic challenges, such as optimal fluid management, maintaining blood pressure, control of body temperature, coagulation and electrolyte derangement and renal toxicity of chemotherapeutic drugs. We have also discussed the postoperative problems and their management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.